Liquid Deprenyl Citrate
This article was originally published in The Tan Sheet
Executive Summary
Discovery Experimental & Development, doing business as Astak, receives FDA warning letter Aug. 16 for claims Liquid Deprenyl Citrate is an effective treatment for diseases including depression, senile dementia, Parkinson's disease, Alzheimer's disease, ALS (Lou Gehrig's disease), high blood pressure, stroke induced paralysis and mental dysfunction. The product is classified by the agency as an unapproved new drug. The Wesley Chapel, Fla.-based firm did not follow the proper procedure when exporting the product to the U.K., FDA adds
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning